ASNDAscendis Pharma A/S
Is it safe?
Nothing alarming, nothing pristine: insiders quiet and typical volatility.
Insiders were net sellers (-$380K, 90 days to Oct 8, 2026), selling is often routine.
Moderate price swings, typical volatility. Worst drawdown -62% · now 15% below its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can ASND take a bad year?
The deepest fall in ASND's price history on file is −62%; it is 16% below its high today.
Net debt · as at Q4 2025 · debt less the cash on hand
- Interest cover
- none
Interest cover · no operating profit to pay the interest bill from
- Annualised volatility
- 40%
Annualised volatility · roughly twice as jumpy as the market
- Worst drawdown on file
- −62%
Worst drawdown on file · −16% today
Details›
- Total debtQ4 2025
- $815M
- Cash and short-term investments
- $616M
- Net debt
- $199M
- Operating profit, trailing twelve months
- −$136M
- Annualised volatilitytwo years of daily moves
- 40%
- Worst drawdown on file
- −62%
- Below its 52-week high
- 16%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.